This resulted in REVLIMIDnet sales of 369

Wasn't the idea for the post-Bonds era in San Francisco to move to younger, up-and-coming playersBack to the question of what Sabean was thinking; in all honesty, Sabean must not have been thinking at all. Even if the 2007 Giants squad was terrible, signing one decent player wasn't going to change anything for the better. But it does leave the Giants in a financial hole, still on the books for $36 million left on Rowand's contract for the next three years.Now some might say that paying $36 million to not play for your team is pointless. However, when a player is doing hardly anything to help his team win, it would be beneficial to give his spot to someone who actually does help the team win.For instance, backup outfielder Andres Torres is making the league minimum this year, as he was a random camp invitee during spring training who was able to crack the roster. Yet despite being essentially a "nobody," Torres has become a fan favorite off the bench because of his speed and his knack for starting rallies.As a natural center fielder, Torres has found limited playing time behind Rowand, but if players were truly given playing time based on performance and not how much they're paid, Torres would see more time than Rowand.On the season, Torres has been quite productive at the plate. Just take a gander at the pair of outfielders' numbers side by side:Rowand: .264/.328/.428/.748, 127 H, 30 2B, 0 3B, 15 HR, 63 RBI, 28 BB, 119KTorres: .260/.333/.512/.845, 33 H, 5 2B 6 3B, 5 HR, 19 RBI, 13 BB, 37KYes, Rowand has a slightly higher average, but when one player has played significantly less than the other, the only statistics that can be truly compared are on-base percentage, slugging percentage, and OPS (the combination of on-base and slugging).By having the advantage in both on-base percentage and slugging, Torres sweeps the three categories from Rowand, not to mention, his strikeout per walk ratio is much lower than Rowand's. Torres averages just 2.84 strikeouts for every walk he draws; Rowand, on the other hand, strikes out 4.25 times for every walk.As a baseball fan, wouldn't you prefer to play the outfielder who reaches base more often, totals more bases when he does reach, and strikes out less not to mention has more range in the outfieldWould it not make logical sense to play the man who is only making $400K because he is performing better than the man making $12 millionWhy don't the Giants just man up and admit that they overpaid for Rowand and that since Torres is the better option right now, he's going to get more playing timeIf anything, it should make Rowand realize that his piss-poor performance isn't cutting it and if he doesn't start to elevate his play, he won't see the field.

On the off chance that Rowand feels insulted by the benching, then he really isn't the "gamer" and team player that he claims to be, because being insulted means he cares more about Aaron Rowand than the San Francisco Giants.Even though the end of the season is almost here, the majority of the Giant faithful cannot stand another at-bat like Rowand had in the bottom of the ninth in the series-opening loss to the Cubs.Giants fans are sick and tired of watching Rowand take the first two strikes called, which range from decent pitches to great pitches to hit, and then swing and miss on the third strike on a ball not even close to thestrike zone.The Giants organization ought to try to find a hardcore Giants fan who disagrees with the statement that Rowand takes pitches he should swing at and swings at pitches he should take. Until they do, they should keep Rowand out of the starting lineup.. SUMMIT, N.J.(Business Wire)Celgene Corporation (NASDAQ: CELG): REVLIMID 1 Therapy in Multiple Myeloma Worldwide European Launch of VIDAZA Commencing REVLIMID U.S. Duration of Therapy Increased Greater Than 25 PercentYear-Over-Year to More Than 10 Months Global Expansion from Nearly 30 to More Than 65 Countries2008 Fourth Quarter Financial Results Year-Over-Year: Non-GAAP Total Revenue Increased More Than 50 Percent to $623 Million; GAAPTotal Revenue $628 Million REVLIMID Net Product Sales Increased 49 Percent to $369 Million Global THALOMID / Thalidomide Net Product Sales $127 Million VIDAZA Net Product Sales Increased to $70 Million Non-GAAP Operating Income Increased Over 45 Percent to $228 Million; GAAPOperating Loss $134 Million (Includes VIDAZA Royalty Buy Back) Non-GAAP Net Income Increased to $201 Million; GAAP Net Loss $149 Million Non-GAAP Earnings Per Share Increased to $0.43 Per Diluted Share; GAAP Loss$0.33 Per Diluted Share2008 Full Year Financial Results Year-Over-Year: Non-GAAP Total Revenue Increased 59 Percent to $2.238 Billion; GAAP TotalRevenue $2.255 Billion REVLIMID Net Product Sales Increased 71 Percent to $1.325 Billion Global THALOMID / Thalidomide Net Product Sales Reached $505 Million VIDAZA Net Product Sales Since the Acquisition of Pharmion in March 2008Reached $207 Million Non-GAAP Operating Income Increased More Than 60 Percent to $848 Million; GAAPOperating Loss $1.464 Billion (Includes Pharmion Acquisition and VIDAZA RoyaltyBuy Back) Non-GAAP Net Income Increased to $719 Million; GAAP Net Loss $1.534 Billion Non-GAAP Diluted Earnings Per Share Increased to $1.56; GAAP Loss $3.46 PerDiluted Share2009 Financial Outlook Year-Over-Year: Non-GAAP Total Revenue Expected to Increase Approximately 20 Percent to aRange of $2.6 Billion to $2.7 Billion REVLIMID Net Product Sales Anticipated to Increase About 28 Percent toApproximately $1.7 Billion VIDAZA Net Product Sales Anticipated to Nearly Double to Approximately $400Million Non-GAAP Diluted Earnings Per Share Expected to Increase Approximately 35Percent to a Range of $2.05 to $2.15Recent Developments and Highlights: European Commercial Rollout of VIDAZA Underway with Initial Launch in Germany The U.S. Patent and Trademark Office Granted New REVLIMID Composition ofMatter Patent with Term to 2026 - Added to Orange Book REVLIMID Now Compendia Listed for Chronic Lymphocytic Leukemia (CLL) in theUnited States The U.S. Patent and Trademark Office Granted New Thalidomide Patent -THALOMID in Combination with Dexamethasone for Blood-Borne Cancers with Term to2017 - Added to Orange Book Initiated Phase II Special Protocol Assessment (SPA) EMERGE Trial inRelapsed/Refractory Mantle Cell Lymphoma (MCL) Received Approval for Two REVLIMID Phase III SPA Trials in CLL The U.S. Patent and Trademark Office Granted Celgene Cellular Therapeutics aComposition of Matter Patent With Broad Claims to Celgene for Placenta-DerivedAdherent Cells (PDAC) More Than 325 Abstracts and 379 Peer-Reviewed Publications on REVLIMID,THALOMID, VIDAZA and Pomalidomide Worldwide REVLIMID and Standard-Dose Dexamethasone Following Stem Cell TransplantResulted in Unprecedented 92 Percent Three-Year Survival Rate - Presented at theAmerican Society of Hematology Meeting Premier Lymphoma International Cooperative Group GELA Selected REVLIMID forPhase III Maintenance Trial in Diffuse Large B-Cell Lymphoma After First LineTherapy Advanced Inflammation Franchise Initiative Through Planning or Initiation ofMore Than 20 Clinical Trials Worldwide Including Initiation of Phase IIInternational Study of Apremilast, Our Lead Oral Inflammation Candidate, inBehcets Disease ACE-011 Results Published in the Journal of Bone and Mineral ResearchHighlighting Unique Mechanism of Action of Activin Biology and the BroadClinical Potential of ACE-011 in a Variety of Diseases Involving Bone Loss,Published Online December 1, 20082009 Selected Corporate Objectives: Maximize the Clinical, Regulatory, and Commercial Potential of REVLIMID,VIDAZA, Global THALOMID/Thalidomide and Pomalidomide in Nearly 75 Countries Execute Launch of VIDAZA in Higher-Risk Myelodysplastic Syndromes (MDS) andAcute Myeloid Leukemia (AML) in the Rest of the European Union Submit REVLIMID Regulatory Filing for MM and Del 5Q MDS in Japan Gain REVLIMID Reimbursement Approvals in UK, Canada, Australia and OtherCountries Submit Data to FDA to Evaluate REVLIMID as Treatment for Newly DiagnosedMultiple Myeloma Advance REVLIMID Lymphoma Initiative Through More Than 46 Clinical TrialsWorldwide Including Initiation of Non-Hodgkins Lymphoma (NHL) Phase III SPATrial in MCL Maintenance Study, as well as Pivotal Phase II SPRINT Trial inRelapsed/Refractory MCL Study Advance REVLIMID Leukemia Initiative Through More Than 35 Clinical TrialsWorldwide Including Initiation of Phase III SPA ORIGIN Trial (CLL-008) inUntreated, Elderly Patients, the Largest Patient Population in CLL, andAdvancing Phase III SPA CONTINUUM Trial in Maintenance CLL Advance Lead Solid Tumor Candidate Amrubicin Phase III Clinical Study in SmallCell Lung Cancer Expand IMiDs Pipeline by Advancing Pomalidomide Clinical and RegulatoryStrategies as Treatment in MM and First-Line Myelofibrosis Advance Global Strategies for Oral Anti-Inflammatory Compound Apremilast inPsoriasis, Psoriatic Arthritis and Ankylosing Spondylitis by Completing PhaseIIb Clinical Trial (PSOR 005) in Moderate-to-Severe Psoriasis as well as PhaseII Dosing Study (PSA-001) in Psoriatic Arthritis Leverage Clinical Potential of Activin Biology by Completing Celgene/AcceleronPhase II Study of ACE-011 in MM Patients With Cancer-Related Bone Loss, as wellas Initiating Phase II Study of ACE-011 in Metastatic Breast Cancer Complete First-in-Class JNK Inhibitor CC-930 Phase Ib Multiple Dose Study inHealthy Volunteers Leading to Clinical Development Programs in Serious FibroticDiseases Complete Phase I Proof-of-Principle Study for Proprietary PDA-001Placenta-Derived Stem Cells in Crohns DiseaseCelgene Corporation (NASDAQ: CELG) announced non-GAAP (Generally AcceptedAccounting Principles) net income of $200.9 million, or non-GAAP earnings perdiluted share of $0.43 for the quarter ended December 31, 2008.

Based on U.S.GAAP, Celgene reported a net loss of $149.3 million, or a loss per diluted shareof $0.33 for the quarter ended December 31, 2008, including the after-tax impactof share-based employee compensation expense of $24.3 million. GAAP net incomefor the fourth quarter of 2007 was $75.3 million, or earnings per diluted shareof $0.18, including the after-tax impact of share-based employee compensationexpense of $15.3 million. Non-GAAP total revenue was $623.4 million for the quarter ended December 31,2008, an increase of more than 50 percent from 2007 GAAP total revenue was$628.3 million. The increase in total revenue was driven by global market sharegains and increased duration of therapy of REVLIMID. This resulted in REVLIMIDnet sales of $369.4 million, an increase of more than 49 percent over the sameperiod in 2007. Global THALOMID/Thalidomide and VIDAZA net sales reached$126.8 million and $69.7 million, respectively. ALKERAN net sales for thefourth quarter of 2008 were $24.4 million compared to $20.0 million in thefourth quarter of 2007.